Novo Nordisk (NVO)
(Delayed Data from NYSE)
$126.95 USD
+1.51 (1.20%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $127.13 +0.18 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Company Summary
Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human insulins. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.
Novo Nordisk operates through two segments: Diabetes and obesity care and Rare disease. While the Diabetes and obesity care segment covers insulins, GLP-1, other protein-related products, obesity and oral anti-diabetic drugs, the Rare diseases segment includes hemophilia, growth hormone therapy and hormone ...
Company Summary
Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human insulins. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.
Novo Nordisk operates through two segments: Diabetes and obesity care and Rare disease. While the Diabetes and obesity care segment covers insulins, GLP-1, other protein-related products, obesity and oral anti-diabetic drugs, the Rare diseases segment includes hemophilia, growth hormone therapy and hormone replacement therapy.
Novo Nordisk’s most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, Ryzodeg, Xultophy, Fiasp, Saxenda, Rybelsus and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.
Wegovy, Novo Nordisk’s other obesity care product, was approved by the FDA in June 2021. Despite facing periodic supply issues, the drug has been recording blockbuster sales figures for the company, boosting its revenues. In March 2024, the drug’s label was expanded by the FDA to reduce the risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack or stroke in adults with either overweight or obesity and established cardiovascular disease.
In September 2023, Novo Nordisk acquired Inversago Pharma, a Montreal-based private company, for an upfront payment of up to $1.075 billion. It added Inversago’s lead development asset INV-202, an oral CB1 inverse agonist, to Novo Nordisk’s diabetes and obesity care portfolio. It also acquired ocedurenone, in 2023, for the treatment of cardiovascular disease from KBP Biosciences, to address the significant unmet need in the treatment of hypertension, which is a leading risk factor for cardiovascular events, heart failure, chronic kidney disease (CKD) and death. Post failure in this indication, the company is now evaluating further development prospects of ocedurenone in other indications.
Novo Nordisk generated revenues of DKK 232 billion in 2023 compared with DKK 177 billion in 2022. Revenues increased 31% in Danish kroner and 36% at the currency exchange rate.
General Information
Novo Nordisk AS
Novo Alle 1
Bagsvaerd, G7 2880
Phone: 45-4444-8888
Fax: 45-4449-0555
Web: http://www.novonordisk.com
Email: investor-relations@novonordisk.com
Industry | Large Cap Pharmaceuticals |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Earnings Date | 11/6/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.91 |
Current Year EPS Consensus Estimate | 3.11 |
Estimated Long-Term EPS Growth Rate | 29.40 |
Earnings Date | 11/6/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 125.44 |
52 Week High | 148.15 |
52 Week Low | 86.96 |
Beta | 0.42 |
20 Day Moving Average | 3,148,426.00 |
Target Price Consensus | 146.86 |
4 Week | -7.21 |
12 Week | -12.27 |
YTD | 21.26 |
4 Week | -8.94 |
12 Week | -15.69 |
YTD | 0.89 |
Shares Outstanding (millions) | 4,487.53 |
Market Capitalization (millions) | 562,916.06 |
Short Ratio | NA |
Last Split Date | 1/9/2014 |
Dividend Yield | 0.58% |
Annual Dividend | $0.72 |
Payout Ratio | 0.45 |
Change in Payout Ratio | 0.11 |
Last Dividend Payout / Amount | 8/16/2024 / $0.36 |
Fundamental Ratios
P/E (F1) | 40.39 |
Trailing 12 Months | 42.96 |
PEG Ratio | 1.37 |
vs. Previous Year | 3.17% |
vs. Previous Quarter | -21.69% |
vs. Previous Year | 23.77% |
vs. Previous Quarter | 3.20% |
Price/Book | 34.67 |
Price/Cash Flow | 41.66 |
Price / Sales | 15.04 |
6/30/24 | 87.43 |
3/31/24 | 91.70 |
12/31/23 | 90.36 |
6/30/24 | 28.01 |
3/31/24 | 29.86 |
12/31/23 | 29.18 |
6/30/24 | 0.94 |
3/31/24 | 0.70 |
12/31/23 | 0.82 |
6/30/24 | 0.75 |
3/31/24 | 0.50 |
12/31/23 | 0.64 |
6/30/24 | 34.86 |
3/31/24 | 36.56 |
12/31/23 | 36.03 |
6/30/24 | 34.86 |
3/31/24 | 36.56 |
12/31/23 | 36.03 |
6/30/24 | 43.81 |
3/31/24 | 45.82 |
12/31/23 | 45.07 |
6/30/24 | 3.62 |
3/31/24 | 3.21 |
12/31/23 | 3.45 |
6/30/24 | 1.22 |
3/31/24 | 1.22 |
12/31/23 | 1.24 |
6/30/24 | 0.46 |
3/31/24 | 0.17 |
12/31/23 | 0.19 |
6/30/24 | 31.44 |
3/31/24 | 14.49 |
12/31/23 | 16.15 |